Advancing the future of diagnostics

Gabriel Fernandez de Pierola is the Genomics & Diagnostic Solutions General Manager at Cytiva, since 2017. He is responsible for the development and commercialization of products and services that enable automatable, cost-effective and reliable technologies for kit developers and end users mainly focusing on genomics. Previously he was the Global Commercial Finance manager for the GE Healthcare Bioprocess business. Gabriel started his career in the GE Capital Financial Management Program in 1999. Gabriel holds a Bachelor of Business Administration degree from ICADE (Spain) and Reims Management School (France).

Priya Hari is a Postdoctoral Genomics Research Fellow at Cytiva with advanced skills in research, cell culture and science communication and is heavily endorsed by the University of Edinburgh. Priya holds a BSc in Medical Biochemistry and a PhD in Cellular Senescence and Tumour Suppression. Alongside her academic achievements, Priya has also been an active STEM Ambassador for over eight years and has published five papers in a range of application areas.

Dr. Hochleitner is a cell and molecular biologist and has covered different roles in the field of membrane research and development, and developing diagnostic tests on solid surfaces. He is working in the field of lateral flow tests for more than 25 years.

Marilena Loizidou is Deputy Director of the Division of Surgery and Interventional Science, Head of Department of Surgical Biotechnology and a Professor of Cancer Nanotechnology at University College London (UCL).

Marilena Loizidou uses nanotechnology tools in cancer pharmacology research. Her main focus has been in the field of novel imaging and targeted therapeutics in solid tumors, mainly colorectal cancer, with a focus on the role of the fibrotic cancer stroma. Marilena co-invented tumoroids, 3D in vitro cultures of cancer which mimic the composition and architecture of solid tumors. Today tumoroids are being developed as platforms for therapeutics and for stratified medicine.

Tom Lyons is Custom Projects Leader at Cytiva, managing custom Sera-Mag™ formulations and conjugation projects. Since graduating from the University of East Anglia with a Masters in Analytical Chemistry with Forensic Sciences in 2008, Tom has gained experience in many research and development roles including British BioCell where he developed lateral flow immunodiagnostic devices and Binx Healthcare (formerly Atlas Genetics), where he developed enzyme stabilization formulations and managed the bulk reagent formulating process. Tom is trained in PRINCE2 project management with a focus on the transfer to manufacture of formulations for InVitro Diagnostic Devices with CE and FDA regulator frameworks.

Luciano G. Martelotto is a cell and molecular biologist and holds a BSc in Biotechnology and a PhD in Biological Sciences. He has a diverse scientific background that includes work in genetics, microbiology, cancer biology, and genomics. Luciano’s current research interests are focused on medical sciences, with special interest in cancer genomics and development and he is dedicated to developing technologies that cross multiple disciplines in order to contribute to society and improve lives.

Sean Mackay co-founded and leads IsoPlexis as CEO. IsoPlexis’ mission is to provide widely accessible cellular proteomics to speed personalized, curative medicines. The company focuses on shifting paradigms in cell and gene therapy, cancer immunology, and infectious disease towards more patient specific, long lasting treatments. IsoPlexis’ easy-to-use instrumentation and software have won numerous awards and are used globally to advance precision medicine.

Previously, Sean helped incubate Kleiner Perkins-backed Lifesquare, which connected patients, payers, and providers through sharing essential healthcare information.  Additionally, through work at Lazard and with several early-stage ventures, he developed a passion for helping life sciences and medical device companies manage in times of strategic change, to deliver their highly needed products to the clinical ecosystem. Sean has co-authored several publications centered around immune medicines and holds patents for a number of single-cell products worldwide.

Dr. Chris Norey is an R&D Leader with over 25 years’ experience in the life sciences industry after gaining a PhD in Biochemistry and Molecular Biology. For the past 10 years Dr. Norey has lead teams responsible for launching over 25 new products, including instrumentation and reagent and consumable products, most recently the Sera-Xtracta™ genomic and cell free nucleic acid isolation kits. He currently leads the genomics R&D team at Cytiva focused on delivering tools for the growing field of genetic based diagnostic applications.

David Raw is the Supplier Risk Management Leader at Cytiva (formerly GE Healthcare Life Sciences) and has worked in supply and sourcing roles in healthcare for more than 13 years. David is passionate about positioning security of supply as a value-based differentiator and a clear value driver of success for patients and Biopharma customers. David holds an MBA in Business Strategy, Supply Chain Management and is also a student mentor/coach at Birmingham University in the UK.

Monika Seidel is the scientific lead on new product development from conception throughout feasibility to manufacturing handover. She has extensive knowledge of liquid biopsy-based diagnostic applications including explain ddPCR (ddPCR) and NGS and expertise in molecular biology, biochemistry, immunology-related techniques, mass spectrometry and stem cell biology. Monika’s research has focused on dissecting molecular mechanisms of human diseases in the field of genomics, proteomics and lipidomics including explain iPSc based(iPSc) modelling of motor neuron degeneration, structure function relationship studies in Ryanodine Receptor 2 associated with sudden cardiac death and siRNA-based high content and high throughput screening for identification of molecular targets and signaling pathways of anti-cancer drugs. She has an M.Sc. degree in Biotechnology, B.Sc. in Organic Chemistry and holds a PhD in Medical Sciences from the University of Cardiff, UK.